Publication
Title
C-terminal neurogranin is increased in CSF but unchanged in plasma in Alzheimer's disease
Author
Abstract
Background: Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimers disease (AD) diagnosis. Post-synaptic protein neurogranin may be a promising CSF biomarker but has not yet been evaluated as plasma biomarker. Methods: Using an in-house designed prototype ELISA targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n=29) versus patients experiencing MCI, or dementia, due to AD (in total n=59). Results: CSF neurogranin was increased in AD and positively correlated with CSF tau while there was a negative relationship between CSF neurogranin (and tau) and CSF Aβ1-42/Aβ1-40. No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter. Conclusions: This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immuno-assays can be used, as demonstrated by the described ELISA.
Language
English
Source (journal)
Alzheimer's & dementia. - Place of publication unknown
Publication
Place of publication unknown : 2015
ISSN
1552-5260
Volume/pages
11:12(2015), p. 1461-1469
ISI
000366721600007
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
[E?say:metaLocaldata.cgzprojectinf]
European Medical Information Framework (EMIF).
Biomarker based adaptive development in Alzheimer (BioAdaptAD).
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 26.05.2015
Last edited 29.07.2017
To cite this reference